Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease

被引：0
|
作者：
Shah, Aditya [1 ]
Sharma, Kamal [2 ]
Rawal, Shalin [1 ]
Sisodia, Rhea [1 ]
Bhatt, Parjanya [1 ]
Christian, Cleris [1 ]
Konat, Ashwati [3 ]
机构：
[1] BJ Med Coll & Civil Hosp, Ahmadabad, Gujarat, India
[2] SAL Hosp, Ahmadabad, Gujarat, India
[3] Gujarat Univ, Dept Zool Biomed Technol & Human Genet, Ahmadabad, Gujarat, India
来源：
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷
关键词：
statins; cost-effectiveness; absolute risk reduction (ARR); incremental cost-effective ratio; generic drug;
D O I：
10.3389/fcvm.2022.916695
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease
    Kohli-Lynch, Ciaran N.
    Lewsey, James
    Boyd, Kathleen A.
    French, Dustin D.
    Jordan, Neil
    Moran, Andrew E.
    Sattar, Naveed
    Preiss, David
    Briggs, Andrew H.
    [J]. CIRCULATION, 2022, 145 (17) : 1312 - 1323
  • [2] Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
    Pandya, Ankur
    Sy, Stephen
    Cho, Sylvia
    Weinstein, Milton C.
    Gaziano, Thomas A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (02): : 142 - 150
  • [3] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [4] The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins
    Walther, Carl P.
    Erickson, Kevin F.
    [J]. KIDNEY INTERNATIONAL, 2019, 96 (01) : 22 - 25
  • [5] Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium
    Neyt, Mattias
    De laet, Chris
    Van Brabandt, Hans
    Franco, Oscar
    Ramaekers, Dirk
    [J]. ACTA CARDIOLOGICA, 2009, 64 (01) : 1 - 10
  • [6] Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease (vol 314, pg 142, 2015)
    Pandya, A.
    Sy, S.
    Cho, S.
    Weinstein, M. C.
    Gaziano, T. A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (15): : 1647 - 1647
  • [7] Smoking cessation for primary prevention of cardiovascular disease: A cost-effectiveness analysis
    Kinderen, AJD
    Oh, F
    De Laet, C
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 692 - 693
  • [8] Primary prevention of cardiovascular disease: a cost-effectiveness comparison
    Franco, O
    De Laet, C
    Der Kinderen, A
    Peeters, A
    Bonneux, L
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 : 122 - 122
  • [9] Primary prevention of cardiovascular disease: Cost-effectiveness comparison
    Franco, Oscar H.
    Kinderen, Arno J. der
    De Laet, Chris
    Peeters, Anna
    Bonneux, Luc
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2007, 23 (01) : 71 - 79
  • [10] Primary prevention of cardiovascular disease: A cost-effectiveness comparison
    Franco, OH
    De Laet, C
    Kinderen, AD
    Peeters, A
    Bonneux, L
    [J]. CIRCULATION, 2004, 110 (17) : 802 - 802
12345